Search Results 521-530 of 17921 for testosterone
- Surgical or medical castration, with serum testosterone ≤ 50 ng/dL (≤ 1.73 nmol/L) at screening - Measurable (extrapelvic soft tissue) metastatic ...
* Has ongoing androgen deprivation with serum testosterone \<50 ng/dL (\<2.0 nM). Treatment with luteinizing hormone-releasing hormone agonists or ...
Patients must have a castrate level of serum/plasma testosterone (< 50 ng/dL or <1.7 nmol/L). Patients must have received at least one NAAD (such as ...
Testosterone and prostate cancer: What's the connection? Transrectal biopsy of the prostate · Types of prostate cancer: Common and rare forms · What is prostate ...
Hormone replacement therapy (HRT) can be a powerful tool for managing menopausal symptoms. It's not for everyone. Learn more.
Prostate cancer: Does PSA level affect prognosis? Prostate gland · SBRT for prostate cancer: How it compares to other treatments · Testosterone and prostate ...
In addition, the relative effect of each treatment strategy on PSA suppression as well as testosterone recovery (and subsequent PSA progression) after 12 ...
PURPOSE: This randomized phase III trial studies testosterone to see how well it works compared to placebo in treating postmenopausal patients with arthralgia ...
Maintain castrate levels of testosterone within 4 weeks prior to randomization and throughout the study; Patients currently receiving bone loss prevention ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.